These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27125809)

  • 1. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia.
    Banks E; Crouch SR; Korda RJ; Stavreski B; Page K; Thurber KA; Grenfell R
    Med J Aust; 2016 May; 204(8):320. PubMed ID: 27125809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute cardiovascular disease risk and lipid-lowering therapy among Aboriginal and Torres Strait Islander Australians.
    Calabria B; Korda RJ; Lovett RW; Fernando P; Martin T; Malamoo L; Welsh J; Banks E
    Med J Aust; 2018 Jun; 209(1):35-41. PubMed ID: 29929455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000.
    Chen L; Rogers SL; Colagiuri S; Cadilhac DA; Mathew TH; Boyden AN; Peeters A; Magliano DJ; Shaw JE; Zimmet PZ; Tonkin AM;
    Med J Aust; 2008 Sep; 189(6):319-22. PubMed ID: 18803535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk perception and evidence--practice gaps in Australian general practice (the AusHEART study).
    Heeley EL; Peiris DP; Patel AA; Cass A; Weekes A; Morgan C; Anderson CS; Chalmers JP
    Med J Aust; 2010 Mar; 192(5):254-9. PubMed ID: 20201758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Under-use of appropriate blood pressure-lowering and lipid-lowering therapy in the Busselton baby boomer population.
    Yiu W; Knuiman M; Wallace H; Hung J
    Aust J Gen Pract; 2019 Dec; 48(12):883-889. PubMed ID: 31774993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cardiovascular disease risk factors, assessment and management in men and women, including consideration of absolute risk: a nationally representative cross-sectional study.
    Banks E; Welsh J; Joshy G; Martin M; Paige E; Korda RJ
    BMJ Open; 2020 Dec; 10(12):e038761. PubMed ID: 33371018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaps in cardiovascular disease risk management in Australian general practice.
    Webster RJ; Heeley EL; Peiris DP; Bayram C; Cass A; Patel AA
    Med J Aust; 2009 Sep; 191(6):324-9. PubMed ID: 19769555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare.
    Hyun KK; Redfern J; Patel A; Peiris D; Brieger D; Sullivan D; Harris M; Usherwood T; MacMahon S; Lyford M; Woodward M
    Heart; 2017 Apr; 103(7):492-498. PubMed ID: 28249996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?
    Selak V; Jackson R; Poppe K; Kerr A; Wells S
    N Z Med J; 2018 Oct; 131(1484):19-25. PubMed ID: 30359352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease.
    Schilling C; Mortimer D; Dalziel K; Heeley E; Chalmers J; Clarke P
    Pharmacoeconomics; 2016 Feb; 34(2):195-205. PubMed ID: 26578402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
    Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
    BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach.
    Jackson R
    J Hum Hypertens; 1998 Sep; 12(9):607-13. PubMed ID: 9783489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).
    Mehta S; Wells S; Riddell T; Kerr A; Pylypchuk R; Marshall R; Ameratunga S; Chan WC; Thornley S; Crengle S; Harrison J; Drury P; Elley CR; Bell F; Jackson R
    J Prim Health Care; 2011 Jun; 3(2):93-101. PubMed ID: 21625656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies.
    Nelson MR; Doust JA
    Med J Aust; 2013 Jun; 198(11):606-10. PubMed ID: 23919708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia.
    Cybulsky M; Cook S; Kontsevaya AV; Vasiljev M; Leon DA
    BMC Cardiovasc Disord; 2016 Jun; 16():122. PubMed ID: 27255373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug prescription rates in secondary cardiovascular prevention in old age: Do vulnerability and severity of the history of cardiovascular disease matter?
    van Peet PG; Gussekloo J; den Elzen WP; Blom JW; de Waal MW; de Ruijter W
    Scand J Prim Health Care; 2015; 33(4):260-8. PubMed ID: 26683286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study.
    Ho CLB; Breslin M; Doust J; Reid CM; Nelson MR
    BMJ Open; 2018 Mar; 8(3):e017723. PubMed ID: 29555790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988-2014.
    Sun X; Du T
    BMC Public Health; 2017 Nov; 17(1):893. PubMed ID: 29166886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.